Initiate a registration trial for EBV-positive lymphoma treatment
Delivered by the deadline
AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.
- Announced
- 24 Feb 2021
- Due
- 30 Jun 2021
- Delivered
- June 2021
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Viracta plans to initiate a registration trial for the treatment of EBV-positive lymphoma in the first half of 2021”
What we found
Evidence strength A What the grades mean
Filings state Viracta initiated NAVAL-1, described as a global pivotal Phase 2 basket trial in EBV+ lymphoma, in June 2021, within the first-half 2021 window. Filings do not use the word registration.
-
A Sunesis Pharmaceuticals Inc. 10-Q filed 2021-08-12
“In June 2021, Viracta announced the initiation of NAVAL-1 (Nanatinostat in Combination with Valganciclovir), a global, multicenter, open-label Phase 2 basket trial” ✓ confirmed on the page
-
A Sunesis Pharmaceuticals Inc. 10-K filed 2022-03-17
“In June 2021, Viracta initiated NAVAL-1, a pivotal, global, multicenter, open-label Phase 2 basket trial of Nan-val for the treatment of multiple subtypes of relapsed/refractory” ✓ confirmed on the page
-
A Sunesis Pharmaceuticals Inc. 8-K filed 2021-08-12
“Initiated NAVAL-1, a global pivotal trial for the treatment of relapsed/refractory EBV-positive lymphoma” ✓ confirmed on the page
Checked 26 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical milestone
- Indicative materiality
- Medium rules
- Action
- Initiate
- Deliverable
- Registration trial for EBV-positive lymphoma treatment
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- Medium
- Specificity
- Medium
- Depends on
- Regulatory
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Claude (Anthropic), read the company's later filings and recorded the outcome with a quoted passage.
Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works
Are you Sunesis Pharmaceuticals Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-C061027-024323 · Corrections policy